Printer Friendly

ROBERTS PHARMACEUTICALS ANNOUNCES ACQUISITION OF THREE MARKETED U.K. AND IRISH BRANDS FROM BOEHRINGER INGELHEIM

 ROBERTS PHARMACEUTICALS ANNOUNCES ACQUISITION OF
 THREE MARKETED U.K. AND IRISH BRANDS FROM BOEHRINGER INGELHEIM
 EATONTOWN, N.J., Dec. 5 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) and Windsor Healthcare Ltd., the United Kingdom OTC subsidiary of Boehringer Ingelheim International GMBH, have announced the completion of an agreement for the acquisition by Roberts of one prescription pharmaceutical product and two non-prescription pharmaceutical products. Roberts UK subsidiary, Monmouth Pharmaceuticals, which will market these products, currently promotes its products through the efforts of 43 contracted sales representatives in the U.K. and eight representatives in Ireland.
 The acquired products, with annual sales of approximately $800,000, include Celevac(R), a bulk forming laxative, Entrotabs(R), anti- diarrheal, and Enterosan(R), high potency anti-diarrheal/anti-spasmodic. "The acquisition of three therapeutically related products from Boehringer Ingelheim allows us to expand our current franchise in the gastrointestinal relief category," said Roberts CEO and chairman, Dr. Robert A. Vukovich. "In addition, the inclusion of these products into the growing Monmouth product portfolio will provide new synergies for our international marketing and promotional programs."
 Anthony Bush, director of Consumer Products at Windsor Healthcare said, "As part of its United Kingdom growth strategy for the 1990s, Windsor is committed to its own acquisition program, having purchased the Hills Balsam cough and cold range in 1990. Earlier this year Boehringer Ingelheim acquired the Pharmaton range of dietary supplements. Windsor will concentrate in the future on these important product areas together with Windsor's branded suncare range, UVISTAT."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non- prescription pharmaceuticals in the United States and abroad. Monmouth Pharmaceuticals markets a line of human pharmaceuticals in the United Kingdom, Republic of Ireland, and the Benelux countries. Monmouth's product line includes MIDON(R), for hypotension, Furacine(R), for burn wounds, Betadur(R), beta blocker, Isomide(R), anti-arrhythmic, and Caprin(R), analgesic.
 -0- 12/5/91
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation; Windsor Healthcare Ltd. ST: New Jersey IN: MTC SU: TNM


SM-OS -- NY056 -- 9700 12/05/91 13:06 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 5, 1991
Words:385
Previous Article:METRO AIRLINES REPORTS NOVEMBER TRAFFIC
Next Article:BUFFTON CORPORATION ANNOUNCES FOURTH QUARTER RESULTS AND ANNUAL LOSS
Topics:


Related Articles
Boehringer Ingelheim Acquires Ben Venue Laboratories in the USA
Boehringer Ingelheim Completes Acquisition of Ben Venue Laboratories in the U.S.
Biofocus plc and Boehringer Ingelheim Pharmaceuticals, Inc. Enter Lead Optimisation Agreement.
Nippon Boehringer Ingelheim Secures 35.86% of SSP Co. Ltd.
Cebert Pharmaceuticals Acquires Worldwide Marketing Rights of Methadone HCL.
Yamanouchi Concludes Co-promotion Agreement with Boehringer Ingelheim Pharmaceuticals Inc. for FLOMAX(R) for the Treatment of the Signs and Symptoms...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters